Pharma Focus Asia

Aptar Pharma Expands its Manufacturing Capacity in New York, USA


Aptar Pharma plans to expand its manufacturing capacity and capabilities in New York, USA.


This expansion involves a building extension, which will contribute an extra 28,500 sq. ft. to the manufacturing footprint, bolstering warehousing, cleanroom, and manufacturing capabilities on-site.

This expansion of the facility offers a larger, state-of-the-art manufacturing space, serving not only to enhance established operations but also to facilitate greater localisation in order to better support the requirements.

The facility's manufacturing capabilities will undergo further expansion to provide even more innovative product solutions and increase production capacity.

This expansion represents a crucial move in the next stage of global growth strategy aimed at ultimately leading to benefits for patients.

This investment will enable to meet the rising demand for its proprietary drug delivery systems in North America. 

To address the increasing demand for systemic nasal delivery by patients, there is a significant expansion underway in the manufacturing capacity for the exclusive Unidose (UDS) Nasal Spray Systems.

The construction of this new environmentally controlled good manufacturing practise (GMP) production area is slated for full operational readiness by early 2025.


Name    Aptar Pharma
Type      Expansion
Year       2025


magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference